P. Gandhi

Triclabendazole in the treatment of human fascioliasis: a review

E. Schmitt, V. Venishetty, Chien-Wei Chen, 2019, Transactions of the Royal Society of Tropical Medicine and Hygiene.

High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine

E. Schmitt, J. Straimer, Katalin Csermak Renner, 2021, The Journal of infectious diseases.

Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum

J. McCarthy, A. Kümmel, J. Jain, 2020, Antimicrobial Agents and Chemotherapy.

Global impact of human fasciolosis.

E. Schmitt, R. Chandra, V. Venishetty, 2021, Fasciolosis.

Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria

Kwaku Poku Asante, E. Karita, A. Oduro, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Preparation and Characterization of Flurbiprofen- Arginine Co-crystals

M. Charde, P. Gandhi, K. Burade, 2021 .

Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa

Kwaku Poku Asante, E. Karita, G. Kullak-Ublick, 2021, Malaria journal.

High prevalence of P. falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine

E. Schmitt, J. Straimer, P. Gandhi, 2021 .

High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine

E. Schmitt, J. Straimer, P. Gandhi, 2021, The Journal of Infectious Diseases.

Defining the next generation of severe malaria treatment: a target product profile

B. Ogutu, S. Duparc, W. Kaszubska, 2024, Malaria journal.